About this item:

132 Views | 194 Downloads

Author Notes:

Patrick C. Hsieh, Department of Neurological Surgery, University of Southern California Keck School of Medicine, 1200 North State Street, Suite 3300, Los Angeles, CA 90033, USA. Email: phsieh@usc.edu

The authors gratefully acknowledge Aaron John Robarts Ferguson for his contributions in performing literature searches, managing citations, data abstraction, and results table editing.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


Research Funding:

Aggregate Analytics, Inc, received funding from AO Foundation to perform the methodological and analytical aspects of this review.

This study was organized and funded by AOSpine International through the AOSpine Knowledge Forum Degenerative, a focused group of international spine oncology experts acting on behalf of AOSpine.

Study support was provided directly through the AOSpine Research Department.


  • allogenic cells
  • fusion
  • stem cells
  • systematic review

Allogenic Stem Cells in Spinal Fusion: A Systematic Review


Journal Title:

Global Spine Journal


Volume 9, Number 1_suppl


, Pages 22S-38S

Type of Work:

Article | Final Publisher PDF


Study Design: Systematic review. Objectives: To review, critically appraise, and synthesize evidence on the use of allogenic stem cell products for spine fusion compared with other bone graft materials. Methods: Systematic searches of PubMed/MEDLINE, through October 31, 2018 and of EMBASE and ClinicalTrials.gov through April 13, 2018 were conducted for literature comparing allogenic stem cell sources for fusion in the lumbar or cervical spine with other fusion methods. In the absence of comparative studies, case series of ≥10 patients were considered. Results: From 382 potentially relevant citations identified, 6 publications on lumbar fusion and 5 on cervical fusion met the inclusion criteria. For lumbar arthrodesis, mean Oswestry Disability Index (ODI), visual analogue scale (VAS) pain score, and fusion rates were similar for anterior lumbar interbody fusion (ALIF) using allogenic multipotent adult progenitor cells (Map3) versus recombinant human bone morphogenetic protein–2 (rhBMP-2) in the one comparative lumbar study (90% vs 92%). Across case series of allogenic stem cell products, function and pain were improved relative to baseline and fusion occurred in ≥90% of patients at ≥12 months. For cervical arthrodesis across case series, stem cell products improved function and pain compared with baseline at various time frames. In a retrospective cohort study fusion rates were not statistically different for Osteocel compared with Vertigraft allograft (88% vs 95%). Fusion rates varied across time frames and intervention products in case series. Conclusions: The overall quality (strength) of evidence of effectiveness and safety of allogenic stem cells products for lumbar and cervical arthrodesis was very low, meaning that we have very little confidence that the effects seen are reflective of the true effects.

Copyright information:

© The Author(s) 2019

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote